Medical marijuana: A treatment worth trying?

,; ,; ,

Applied Evidence

Medical marijuana: A treatment worth trying?

J Fam Pract. 2016 March;65(3):178-185

PDF Download

References

1. Office of National Drug Control Policy. Marijuana Resource Center. State Laws Related to Marijuana. Available at: https://www.whitehouse.gov/ondcp/state-laws-related-to-marijuana. Accessed December 12, 2015.

2. American Academy of Family Physicians. AAFP policies: marijuana. Available at: http://www.aafp.org/about/policies/all/marijuana.html. Accessed January 16, 2016.

3. American College of Physicians. Supporting research into the therapeutic role of marijuana. Available at: https://www.acponline.org/acp_policy/policies/supporting_medmarijuana_2008.pdf. Accessed January 26, 2016.

4. Institute of Medicine. Marijuana and medicine: assessing the science base. Available at: http://iom.nationalacademies.org/reports/1999/marijuana-and-medicine-assessing-the-science-base.aspx. Accessed January 26, 2016.

5. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456-2473.

6. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313:2474-2483.

7. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo controlled trial. Lancet. 2003;362:1517-1526.

8. Zajicek JP, Hobart JC, Slade A, et al. MUSEC research group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83:1125–1132.

9. Koppel BS, Brust JCM, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556-1563.

10. Kahan M, Srivastava A, Spithoff S, et al. Smoked CB for chronic noncancer pain. Can Fam Physician. 2014;60:1083–1090.

11. Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Network. 2012;10:487-492.

12. Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systemic review. BMJ. 2001;323:16-21.

13. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20:567-573.

14. Hu SS, Mackie K. Distribution of the endocannabinoid system in the central nervous system. Handbook Exp Pharmacol. 2015;231:59-93.

15. Bhattacharyya S, Morrison PD, Fusar-Poli P. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35:764-774.

16. Hazekamp A, Ware MA, Muller-Vahl KR, et al. The medicinal use of cannabis and cannabinoids – an international cross sectional survey on administration forms. J Psychoactive Drugs. 2013;45:199-210.

17. ProCon.org site. 10 pharmaceutical drugs based on cannabis. Available at: http://medicalmarijuana.procon.org/view.resource.php?resourceID=000883. Accessed January 28, 2016.

18. Cerda M, Wall M, Keyes KM, et al. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana, abuse and dependence. Drug Alcohol Depend. 2012;120:22-27.

19. US Food and Drug Administration. Inter-agency advisory regarding claims that smoked marijuana is a medicine. April 20, 2006. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108643. Accessed January 29, 2016.

20. Marinol dronabinol capsules. Available at: www.marinol.com. Accessed January 29, 2016.

21. Cesamet full prescribing information. Available at: http://www.cesamet.com/patient-home.asp. Accessed January 29, 2016.

22. Aoyagi T, Terracini KP, Raza A, et al. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 2015;7:17-29.

23. Strasser F, Laftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9 tetrahydrocannabinol (THC) in treating patients with cancer-related anorexia cachexia syndrome, a multicenter, randomized, double blind controlled clinical trial from the Cannabis-In Cachexia Study Group. Clin Oncol. 2006;24:3394 -3400.

24. Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev. 2013;(4):CD005175.

25. Phillips JA, Holland MG, Baldwin DD. Marijuana in the workplace: guidance for occupational health professionals and employers: Joint Guidance Statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine. J Occup Environ Med. 2015;57:459-475.

26. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Phys. 2012;15:ES67-ES92.

27. Lopez-Quintero C, de los Cabos JP, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011:115:120-130.

28. Strobbe S. Prevention and screening, brief intervention and referral to treatment for substance use in primary care. Primary Care. 2014;41:185-213.

29. Ehlers CL, Gizer IR, Vieten C, et al. Cannabis dependence in the San Francisco Family Study: age of onset of use, DSM-IV symptoms, withdrawal, and heritability. Addict Behav. 2010;35:102-110.

30. American Society of Addiction Medicine. Drug testing: a white paper of the American Society of Addiction Medicine. Available at: http://www.asam.org/docs/default-source/publicy-policy-statements/drug-testing-a-white-paper-by-asam.pdf?sfvrsn=2. October 26, 2013. Accessed January 26, 2016.

31. Tomar RS, Beaumont J, Hsieh JCY. Evidence on the carcinogenicity of marijuana smoke. California EPA: Reproductive and Cancer Hazard Assessment Branch of the Office of Environmental Health Hazard Assessment. August 2009. Available at: http://oehha.ca.gov/prop65/hazard_ident/pdf_zip/FinalMJsmokeHID.pdf. Accessed January 29, 2016.

32. Salomonsen–Sautel S, Sakai JT, Thurstone C. Medical marijuana use among adolescents in substance abuse treatment. J Am Acad Child Adolesc Psychiatry. 2012;7:694-702.

33. Reisfield GM, Goldberger BA, Bertholf RL. ‘False-positive’ and ‘false-negative’ test results in clinical urine drug testing. Bioanalysis. 2009;1:937-952.

What’s more, marijuana remains classified as a Schedule I agent.¹⁹ Because of its high potential for abuse, physicians in states where medical marijuana has been legalized should adhere to off-label prescribing principles: Recommend it only after standard medications, including FDA-approved cannabinoids, and nonpharmaceutical approaches have proven to be inadequate.^6,20,21

Marijuana’s therapeutic effects depend on the concentration of THC in a formulation and on the ratio of THC to cannabidiol.

Medical marijuana for your patient? A look at the evidence

The meta-analysis cited earlier included 79 randomized clinical trials (RCTs) of medical marijuana used for a variety of conditions in a number of delivery modes. However, only 4 were judged to be of low risk of bias.⁵ Nonetheless, here’s a look at this and other evidence.

Chronic and neuropathic pain

Twenty-eight of the 79 studies addressed chronic pain, with half assessing the oromucosal spray (nabiximols). Most others studied marijuana that was smoked or inhaled. Neuropathic pain was most frequently studied, but cancer pain, fibromyalgia, and musculoskeletal pain, among others, were also evaluated.⁵

The average number of patients who reported a reduction in pain of ≥30% was greater with marijuana compared with placebo (odds ratio=1.41; 95% confidence interval, .99-2.0). Delivery mode did not affect outcomes; different forms of administration were not associated with any significant difference in pain relief. Nor were there significant differences in results among the various pain conditions studied. Notably, however, quality of life measurements did not reflect any overall improvement.⁵

The authors of a literature review of marijuana for chronic and neuropathic pain and MS-induced spasticity did find high-quality evidence of its efficacy in several of the trials they assessed.⁶ And a review of well-conducted observational trials of smoked marijuana as a treatment for severe neuropathic pain revealed that it may be indicated for those who fail to respond to FDA-approved cannabinoids and standard analgesics.¹⁰ Neither functional status nor quality of life was evaluated, however, and none of the observational studies compared smoked cannabis to standard analgesics.

Notably, the authors did not recommend smoked marijuana for pain conditions such as low back pain and fibromyalgia, which are commonly seen in practice. That’s because the safety and efficacy of smoked cannabis has not been studied for these conditions and because evidence-based treatments for these disorders exist.¹⁰

CASE › Before considering medical marijuana for Ms. B, you suggest a trial of dronabinol. The patient agrees, and you prescribe 2.5 mg twice a day. You schedule a visit in 4 weeks to review the drug’s efficacy and tell her to call if she develops psychiatric symptoms, such as hallucinations or paranoia, or impaired cognition. You also advise her that dronabinol may increase the risk of auto accidents and caution her to avoid driving for 6 hours after taking the drug—or longer if she experiences an initial “high.”

MS symptoms

A comprehensive review of medical marijuana studies spanning nearly 7 decades revealed 12 trials focusing on MS—and found its use in treating MS-related spasticity supported by high-quality evidence.⁶

Those taking cannabinoids were more likely than patients taking other antiemetics to withdraw from studies due to adverse effects, such as dizziness and hallucinations.

Two of the largest studies were done in the UK.^7,8 One multicenter trial included 630 participants randomized to treatment with an oral cannabinoid extract, THC, or placebo for 6 weeks.⁷

There was no change in the primary outcome measure, the Ashworth spasticity scale. However, there was a treatment effect on patient-reported spasticity and pain, with improvement in spasticity reported by 61% of those treated with the cannabinoid extract, 60% of those treated with THC, and 46% of those treated with placebo.⁷

The other UK trial involved 22 centers and 279 patients, randomized to either oral cannabis extract or placebo. The primary outcome measure involved a category rating scale that reported on change in muscle stiffness since baseline and on body pain, spasms, and sleep quality. This study used a 2-week titration phase and a 10-week maintenance phase. The rate of relief from muscle stiffness after 12 weeks was almost twice as high in the cannabis extract group (29%) compared with placebo (16%).⁸

A systematic review of the efficacy and safety of medical marijuana by the American Academy of Neurology (AAN) concluded that oral cannabis extract, THC, and nabiximols are “probably effective” in reducing patient-centered measures of spasticity and pain associated with MS.⁹

Little help for other neurologic disorders. Studies of the efficacy and safety of medical marijuana for other neurologic disorders have been less encouraging. The AAN concluded that cannabinoids are probably ineffective for the treatment of tremors, and that oral cannabis extract is probably ineffective for treating levodopa-induced dyskinesias in patients with Parkinson’s disease.